Tatsuki Yokoseki

This inventor holds 6 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: Immunas Pharma, Inc., National Center for Geriatrics and Gerontology. Active years: 2013-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tatsuki Yokoseki. Retrieved from https://idiyas.com/inventor/tatsuki-yokoseki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 3)

% Patents Active = 83.3

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 4.2

ph-index = 3

Forward Citations = 43(Granted Patents)

Company Filing History:

National Center for Geriatrics and Gerontology

patents

where one patent can have more than one assignee

Years Active: 2013-2015

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9090680 - Antibodies that specifically bind to abeta oligomers and uses thereof (2015-07-28),

2. 9090679 - Antibodies that specifically bind to A beta oligomers and use thereof (2015-07-28),

3. 9085614 - Antibodies that specifically bind to Aβ oligomers and uses thereof (2015-07-21),

4. 8858949 - Antibodies that specifically bind to a beta oligomers and use thereof (2014-10-14),

5. 8613924 - Antibodies that specifically bind to A beta oligomers and use thereof (2013-12-24),

6. 8378081 - Antibodies that specifically bind to Aβ oligomers and uses thereof (2013-02-19),

Title: Innovations of Tatsuki Yokoseki in Alzheimer's Disease Research

Introduction

Tatsuki Yokoseki is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of Alzheimer's disease research through his innovative work in monoclonal antibodies. With a total of six patents to his name, Yokoseki's inventions are paving the way for advancements in diagnostic and therapeutic approaches to this debilitating condition.

Latest Patents

Yokoseki's latest patents focus on antibodies that specifically bind to A beta oligomers. These antibodies have been successfully produced to recognize only soluble A beta oligomers while avoiding soluble A beta monomers, which are physiological molecules. This specificity is crucial as it demonstrates the potential of these antibodies as diagnostic and therapeutic tools for Alzheimer's disease. The innovative nature of these patents highlights Yokoseki's commitment to addressing the challenges posed by this neurodegenerative disorder.

Career Highlights

Throughout his career, Tatsuki Yokoseki has worked with notable organizations such as Immunas Pharma, Inc. and the National Center for Geriatrics and Gerontology. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research in Alzheimer's disease.

Collaborations

Yokoseki has collaborated with esteemed colleagues, including Yasuhide Okamoto and Makoto Umeda. These partnerships have further enriched his research and have been instrumental in the development of his innovative patents.

Conclusion

Tatsuki Yokoseki's work in the field of Alzheimer's disease research exemplifies the impact of innovation in medicine. His patents on monoclonal antibodies represent a significant step forward in the quest for effective diagnostic and therapeutic solutions.

Profile summary based on public USPTO records.